Formulation and evaluation of carvedilol microcapsules using Eudragit NE30D and sodium alginate

Trishna Bal¹*, Shubhranshu Sengupta², Padala Narasimha Murthy³

¹Department of Pharmaceutical Sciences, Birla Institute of Technology, Jharkhand, India, ²Department of Horticulture, Birsa Agriculture University, Jharkhand, India, ³Royal College of Pharmacy and Health Sciences, Orissa, India

Inclusion complexes of carvedilol (CR) with hydroxyl propyl beta-cyclodextrin (HPBCD) was prepared using co-grinding technique. Then, the inclusion complex was microencapsulated using combinations of Eudragit NE30D (EU) and sodium alginate (SA) utilizing orifice gelation technique. The formulations were analysed by using Scanning electron microscopy (SEM), Fourier Transform Infrared spectroscopy (FTIR), Differential scanning Calorimetry (DSC) and X-ray diffractometer (XRD) and also evaluated for particle size, encapsulation efficiency, production yield, swelling capacity, mucoadhesive properties, zeta potential and drug release. The microcapsules were smooth and showed no visible cracks and extended drug release of 55.2006% up to 12 hours in phosphate buffer of pH 6.8, showing particle size within the range of 264.5-358.5 µm, and encapsulation efficiency of 99.337±0.0100-66.2753±0.0014%. The in vitro release data of optimized batch of microcapsules were plotted in various kinetic equations to understand the mechanisms and kinetics of drug release, which followed first order kinetics, value of “n” was calculated to be 0.459 and drug release was diffusion controlled. The mice were fed with diet for inducing high blood pressure and the in vivo antihypertensive activity of formulations was carried out administering the optimized formulations and pure drug separately by oral feeding and measured by B.P Monwin IITC Life Science instrument and the results indicated that the bioavailability of carvedilol was increased both in vitro and in vivo with the mucoadhesive polymers showing primary role in retarding the drug release.

INTRODUCTION

The most desirable and convenient method of drug administration is the oral route (Patil et al., 2009). Carvedilol (CR) is a nonselective β-adrenergic blocking agent with α₁-blocking activity. It is well absorbed from the gastrointestinal tract but subjected to considerable first-pass metabolism in the liver (Tanwar, Chauhan, Sharma, 2009) and its oral bioavailability in humans is only 20% (Gurav et al., 2009). The drug has a short half-life of 2.2 ± 0.3 h. The drug is formulated with a series of polymers to improve the absorption and prolong the half-life, thereby preventing degradation in gastric region. Since the drug has low bioavailability due to poor water solubility and slow dissolution rates (Hirlekar, Kadam, 2009) several methods are used to improve the solubility profile of CR, of which complexation with cyclodextrins has been widely used to improve the solubility and dissolution rate of poorly soluble drugs (Wang et al., 2006; Archontaki et al., 2002). Cyclodextrins (CDs) are macrocyclic oligosaccharides with six to eight D-glucose units called α-Cyclodextrin, β-Cyclodextrin and γ-Cyclodextrin. The most important property of CDs is that they have hydrophobic central cavities capable of forming stable complexes with properly sized drug molecule (Vyas, Saraf, Saraf, 2008; Shewale et al., 2008; Bhutani et al., 2007). Among the various CDs, hydroxypropyl beta-cyclodextrin (HPBCD) is most successful in improving the dissolution rate (Pitha et al., 1986) of poorly soluble drugs.

Polymeric microparticles are recommended for oral, nasal or pulmonary administration. These systems are able to promote extended release of a bioactive compound and also can protect the drug from degradation and physiological metabolism (Salsa, Veiga, Pina, 1997). In order to develop microcapsules, several polymers both from natural and synthetic sources can be used (Deasy, 1984).

The present work is mainly focussed on improving the solubility characteristics of CR by use of CDs, mainly HPBCD by formation of binary systems of CR/ HPBCD in a 1:1 ratio (w/w ratio) and then formulating this binary system in the form of microcapsules using Orifice Gelation technique, by the use of some mucoadhesive hydrophilic polymers like Sodium alginate and an aqueous dispersion of Eudragit NE30D for oral use. The optimized microcapsules were then evaluated in vitro to determine the drug release and in vivo to determine the efficacy of the formulations.

MATERIAL AND METHODS

Material

Carvedilol(CR) was kindly gifted by Glenmark Pharmaceuticals (Mumbai, India), hydroxypropyl beta-cyclodextrin (HPBCD) was kindly gifted by Roquette (Lestrem, France), sodium alginate (SA) was purchased from Loba Chemicals(India); Eudragit NE30D (EU) was a gift sample from Evonik Degussa Rohm Pharma (Mumbai, India). All other chemicals used were of analytical reagent grade purity.

Preparation of Microcapsules

The method used for the preparation of microcapsules adopted was Orifice Gelation technique (Chowdary, Rao, 2003). Binary system of HPBCD/CR was prepared by co-grinding technique (Hirlekar, Kadam, 2009) in which mixing of CR in a ratio of 1:1(w/w ratio) with HPBCD in a glass mortar for 30 minutes was done , and stored in a desiccator. Then this binary system was mixed with SA and EU separately for formulating different batches of microcapsules as stated in Table I. The physical mixtures (PM) (of the CR along with HPBCD, SA and Eudragit NE30D) were analyzed separately for any possible drug-

<table>
<thead>
<tr>
<th>Formulation Code</th>
<th>Drug (carvedilol): hydroxypropyl beta-cyclodextrin (HPBCD) (mg)</th>
<th>sodium alginate(SA) (mg)</th>
<th>Eudragit NE30D(EU) (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRSAEU1</td>
<td>1:1</td>
<td>600</td>
<td>200</td>
</tr>
<tr>
<td>CRSAEU2</td>
<td>1:1</td>
<td>600</td>
<td>400</td>
</tr>
<tr>
<td>CRSAEU3</td>
<td>1:1</td>
<td>600</td>
<td>600</td>
</tr>
<tr>
<td>CRSAEU4</td>
<td>1:1</td>
<td>200</td>
<td>600</td>
</tr>
<tr>
<td>CRSAEU5</td>
<td>1:1</td>
<td>600</td>
<td>1050</td>
</tr>
<tr>
<td>CRHPSAI</td>
<td>1:1</td>
<td>1000</td>
<td>----------------------</td>
</tr>
</tbody>
</table>
excipient interactions. The binary system of HPBCD/CR was triturated with SA and then mixed with Eudragit NE30D in a glass mortar pestle and dispersed this mixture in millipore water (obtained from Elix millipore water filter) using magnetic stirrer for 30 min at 200 rpm and allowed to form uniform slurry named as “CRV”. A 3%w/v calcium chloride solution was prepared and filtered separately and to this solution, the slurry “CRV” was added dropwise through a 10 mL syringe (Dispovan) having needle of size no.26G. The microcapsules formed were allowed to remain in the calcium chloride solution for 30 min to complete the curing reaction. The formed microcapsules were filtered and washed with millipore water to remove any traces of calcium chloride from the microcapsule surfaces and dried the microcapsules in open air and kept in a desiccator.

**Evaluation of microcapsules**

**Determination of Yield of Production**

The production yields (Ranjha, Khan, Nazeem, 2010) of microspheres of various batches were calculated using the weight of finally dried microspheres with respect to the initial total quantity of the drug and polymer used for preparation. Percent production yields were calculated as per the formula below:

\[
\text{Production yield} = \frac{\text{Practical mass (microspheres)}}{\text{Theoretical mass (polymer + drug)}} \times 100
\]

**Determination percentage encapsulation efficiency**

Percentage encapsulation efficiency is the percentage of drug encapsulated in the microcapsules related to the initial quantity of the drug used in the formulation. 100 mg of microcapsules were taken and crushed in a glass mortar-pestle. In a 100 mL volumetric flask, the grounded microcapsule powder was mixed with methanol to make up the volume up to 100 mL and placed the whole system in a sonicator for 30 min to get the maximum extraction of CR in the solvent. The sample so obtained were filtered to obtain clear solution and assayed for the drug content spectrophotometrically at 242 nm. Percent encapsulation efficiency (Ranjha, Khan, Nazeem, 2010) was determined by using the formula below.

\[
\text{Percentage Encapsulation efficiency} = \frac{\text{Actual Drug Content (mg)}}{\text{Practical drug Content (mg)}} \times 100
\]

- **Particle Size**

  The Particle size of the dried microcapsules was measured using a stage micrometer scale by optical microscopy method. This study was done in triplicate. 100 nos. of dry microcapsules were placed on a clean glass slide and a few drops of liquid paraffin was added and covered with a glass slide and observed under a compound microscope using stage and ocular micrometer (Dhaliwal et al., 2008; Patil et al., 2009).

- **Determination of bulk density**

  The bulk density of the formulations was determined by using the following formula (Ranjha, Khan, Nazeem, 2010). This study was done in triplicate.

  \[
  \text{Bulk density} = \frac{\text{Sample Weight}}{\text{Sample Volume}}
  \]

- **Determination of Tapped density**

  Tapped Density is used to investigate packing properties of microcapsules into capsules. The Tapped density was measured by employing the conventional tapping method using a 10ml measuring cylinder and the number of tapings was 100 as sufficient to bring a plateau condition. This study was done in triplicate. Tapped density was calculated by using the following formula (Ranjha, Khan, Nazeem, 2010):

  \[
  \text{Tapped density} = \frac{\text{Weight of the microspheres}}{\text{Volume of microcapsules after 100 tappings}}
  \]

- **Determination of Carr’s consolidation Index**

  It is indirect measurement of bulk density, size and shape, surface area, moisture content and cohesiveness of materials since all of them can influence the consolidation index. It is also called as Compressibility index (Ci). This study was done in triplicate. It is denoted by Ci and is calculated using the formula below (Ranjha, Khan, Nazeem, 2010):

  \[
  \text{Ci} = \frac{\text{Tapped density} - \text{Bulk density}}{\text{Bulk density}}
  \]

  A Carr’s index less than 15% is referred to as very good flow, 16-26% is good, 27-35% is fairly good and ≥35% are considered as poor (Carr, 1965).

- **Determination of Hausner’s ratio**

  It is another parameter for measuring flowability of the microcapsules. This study was done in triplicate. It is calculated using the following formula (Ranjha, Khan, Nazeem, 2010):

  \[
  \text{Hausner’s ratio} = \frac{\text{Volume before tapping}}{\text{Volume after tapping}}
  \]

- **Determination of Angle of repose**

  Angle of repose (θ=\tan^{-1} h/r) of the microcapsules was determined by passing the microcapsules through
the glass funnel on a horizontal surface (Ranjha, Khan, Nazeem, 2010). This study was done in triplicate. The height (h) of the heap formed was measured and the radius (r) of the cone base was also observed and calculated.

- Percentage of swelling of Microcapsules
  Swelling rate of the microcapsules was measured as a function of water uptake. The formulations were placed in phosphate buffer of pH 6.8 at room temperature for a time period of 10 hours. At different time intervals, the microcapsules were taken out and very gently pressed with a tissue paper to remove the excess liquid and then weighed. These studies were done in triplicate. The percentage swelling of the microcapsules was determined by using the following formula as below (Patil Sanjay, Sawant Krutika, 2009):

  \[
  \text{% Water uptake} = 100 \times \frac{\text{Weight of wet microcapsules} - \text{Weight of dry microcapsules}}{\text{Weight of dry microcapsules}}
  \]

- Mucoadhesion properties of the microcapsule
  Bioadhesive strength of the microcapsules was measured on a modified physical balance using the method described by Gupta, Garga and Khar (1992). Carbopol 934P which was taken as standard to compare the mucoadhesivity of microcapsules. The microcapsules were sandwiched between two mucosal surfaces of rat intestine. The intestine were placed on two oppositely placed platforms of two slides, one hanged to the left pan of balance and other placed on a water bath at the base. Then weights were placed to the right pan of the balance in ascending order starting from lower weights and after each addition of weights, allowing to stand for 1 min, and then added the next weight and this process was continued till the two mucosal surfaces detached from one another on the left side of pan and thus the detachment force required to separate two glass slides was measured. This study was done in triplicate.

**In vitro Drug release of microcapsules**

900 mL of phosphate buffer of pH 6.8 (Hirlekar, Kadam, 2009) was taken as dissolution medium for in vitro drug release in USP Type-I dissolution apparatus. 100mg of the microcapsules were taken and filled in a hard gelatin capsule and placed in the basket and started the dissolution at 75 rpm and continued the study for a period of 13 hours. 5ml of sample was withdrawn after every 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 hours and analyzed spectrophotometrically at 241 nm and calculated the cumulative drug release and calculated the drug release kinetics. This study was done in triplicate. The statistical ANOVA analysis of the in vitro release studies is also plotted.

Data obtained from in vitro release studies were fitted to various kinetic equations to find out the mechanisms of the drug release. The kinetic models used were Zero order equation, first order Equation, Higuchi equation, Hixson Crowell Equation, Peppas-Korsmeyer Equation.

**Physicochemical evaluations of microcapsules**

- FTIR spectroscopy (Ranjha, Khan, Nazeem, 2010)
  Binary System (HPBCD/CR)–Polymers interactions were studied by FTIR spectroscopy (FTIR Shimadzu 8400S). Also the spectra for pure drug and drug loaded microcapsules were recorded. Samples were prepared in KBr disks (2 mg sample in 200 mg of KBr). The scanning was 400-4000 cm\(^{-1}\) and the resolution was 2 cm\(^{-1}\).

- X-ray powder diffractometry
  This technique was carried out to investigate the effect of polymers and complexing agent HPBCD on the characteristics of the drug after formulation. Powdered samples of pure drug, polymers, HPBCD and microcapsules were irradiated with monochromatized X-rays (Cu-\(\kappa\)) of 30kV and 15mA current in a Rigaku analytical XRD (Model Miniflex, Japan). The scanning rate employed was 0.2\(^{0}\) min\(^{-1}\) of 2\(\theta\). The X-ray powder diffractometry (X-RD) patterns of the drug and drug loaded microcapsules were recorded (Ranjha, Khan, Nazeem, 2010).

- DCS studies of the microcapsule (Ranjha, Khan, Nazeem, 2010; 5 mg weight of samples (Pure drug, Polymers, optimized microcapsule) were taken to carry out tests in DSC using Aluminium sample pans at a scanning speed of 10 \(^{\circ}\)C per min form 10 \(^{\circ}\)C-200 \(^{\circ}\)C to detect any interaction between drug and polymers.

**Morphological studies of microcapsules**

The optimized batch of microcapsules used for determination of surface morphology were coated by gold sputtering technique and observed using the Scanning electron microscope (Ranjha, Khan, Nazeem, 2010) (Model Jeol Japan; JSM-6390LV).

**Determination of zeta potential of microcapsules**

The optimized batch of formulation was dispersed in phosphate buffer of pH 6.8 and the surface charge (zeta potential) was measured by laser doppler anemometry using a Zetamaster (Malvern, UK) (Patil Sanjay, Sawant,
Krutika, 2009). Also the zeta potential of the individual polymers and the drug were measured for a comparative study.

In vivo animal studies
- **Animals**
  Male swiss albino mice weighing from 100-120 g were housed in a temperature and light controlled room (23±2°C; 12 hours light/dark cycle), with free access to water and food. All the procedures are in agreement to the Institutional animal ethical committee, BIT, Mesra, Ranchi (vide letter No.CPCSEA approval no: 621/02/ac/CPCSEA).

**Experimental protocol**
Eighteen male mice of eight weeks old were randomly selected and divided in three groups of 6 animals each of weight of 20-50 g. Group 1 received pure carvedilol (CR); Group 2 received optimized formulation CRSAEU5 \( \text{[at 10 mg/kg (Schaefer et al., 1998)]} \); Group 3 was taken as the control (without any drug or formulations, only provided with water and normal food). For all the three groups initially, before any treatment, the mice were acclimatized for 3 days in the warming chamber of the B.P Monwin IITC Life Science instrument. On the 4th day, blood pressure was measured by noninvasive tail cuff method using B.P Monwin IITC Inc. Life Science instrument. Then for one week the animals of Group 1 & 2 were given diet as given in Table II for inducing Hypertension (Qianli et al., 2004). After one week, the B.P was again measured for all the three groups to observe the increase in B.P and after confirming that there is induction of hypertension, treatment was started with pure drug CR and optimized microcapsules batch CRSAEU5 in two different groups respectively.

**Statistical evaluations for In-vivo studies of optimized carvedilol microcapsules in mice**
The data of statistical ANOVA one way analysis was calculated in Graph Pad software in mice for optimized formulations of carvedilol CRSAEU5 is presented in Figure 7 and Figure 8. The IITC life sciences Blood pressure (B.P) measuring instrument for mice which was utilized during the experiment is presented in Figure 9.

**RESULTS AND DISCUSSION**

**Effect of technique on the formation of microcapsules**
Mucoadhesive carvedilol microcapsules prepared by orifice Gelation technique using a mixture of natural polymers and aqueous dispersion of ethylcellulose i.e. Eudragit NE30D were found to be free flowing and almost spherical in shape. The preparation method used was advantageous for entrapment of water-insoluble drugs. Moreover by formation of binary system of HPBCD/CR, solubility parameter of drug CR was increased. The production of microcapsules varied with different ratios of polymers. The results are shown in Table III. The high yield of the microcapsules may be due to the entire mass

**TABLE II - Diet Composition for mice for inducing Hypertension** (Qianli et al., 2004)

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Amount (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein</td>
<td>14</td>
</tr>
<tr>
<td>Fat</td>
<td>20</td>
</tr>
<tr>
<td>Fiber</td>
<td>0.5</td>
</tr>
<tr>
<td>Carbohydrate</td>
<td>10</td>
</tr>
<tr>
<td>Mineral Mix</td>
<td>0.35</td>
</tr>
<tr>
<td>Vitamin Mix</td>
<td>0.1</td>
</tr>
<tr>
<td>NaCl</td>
<td>8</td>
</tr>
</tbody>
</table>

**TABLE III - Micromeritic properties along with encapsulation efficiency, %yield and assessment of mucoadhesivity of formulations**

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Formulation Code</th>
<th>% Encapsulation efficiency (%E.E)</th>
<th>% Yield</th>
<th>Particle Size (µm)</th>
<th>Mucoadhesivity [Detachment Strength (N/Cm²)]</th>
<th>Assessment of Duration of Mucoadhesion in (min)</th>
<th>% C.I</th>
<th>Hausner's Ratio</th>
<th>Angle of Repose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CRSAEU1</td>
<td>66.275±0.0014</td>
<td>91.1529</td>
<td>317.5±15.08</td>
<td>0.021909</td>
<td>1.4±0.100</td>
<td>9.1±0.152</td>
<td>1.09±0.009</td>
<td>13.2±0.4612</td>
</tr>
<tr>
<td>2</td>
<td>CRSAEU2</td>
<td>78.759±0.001</td>
<td>88.6315</td>
<td>335.0±11.527</td>
<td>0.021582</td>
<td>1.5±0.0577</td>
<td>9.1±0.152</td>
<td>1.09±0.009</td>
<td>12.19±0.5411</td>
</tr>
<tr>
<td>3</td>
<td>CRSAEU3</td>
<td>82.598±0.0005</td>
<td>81.6</td>
<td>358.5±11.527</td>
<td>0.021909</td>
<td>1.4±0.100</td>
<td>15.96±0.647</td>
<td>1.16±0.0055</td>
<td>12.103±0.3874</td>
</tr>
<tr>
<td>4</td>
<td>CRSAEU4</td>
<td>98.8248±0.0012</td>
<td>86.206</td>
<td>291.5±12.527</td>
<td>0.022236</td>
<td>1.5±0.100</td>
<td>25±0.7637</td>
<td>1.25±0.009</td>
<td>15.13±0.39004</td>
</tr>
<tr>
<td>5</td>
<td>CRSAEU5</td>
<td>99.337±0.0100</td>
<td>91.636</td>
<td>264.5±7.527</td>
<td>0.023217</td>
<td>1.6±0.100</td>
<td>8.3±0.1301</td>
<td>1.083±0.0012</td>
<td>11.24±0.4652</td>
</tr>
<tr>
<td>6</td>
<td>CRHPSAI</td>
<td>65.84±0.080</td>
<td>85.71</td>
<td>358.5±11.527</td>
<td>0.022236</td>
<td>1.33±0.3055</td>
<td>14.3±0.7419</td>
<td>1.14±0.0100</td>
<td>12.0115±0.245</td>
</tr>
<tr>
<td>7</td>
<td>Carbopol 934P</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>0.0256041</td>
<td>1.5±0.100</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
</tbody>
</table>
of the polymer available for gelation by the crosslinking agent. These studies were done in triplicate.

As the drug is water insoluble, so most of the drug got entrapped in the polymer matrix resulting higher drug content and high percentage encapsulation efficiency. Moreover as the amount of both the polymers increased, the entrapment efficiency also increased.

**Micromeritic properties**

As observed in Table III, the particle size of the different batches of microcapsules ranged from 264.5-358.5 µm as determined by optical microscopy method. The formulation CRSAEU5 showed the least particle size of 264.5 µm±1.527 among the other formulations, showing that is a better formulation. Moreover as seen from Table III, CRSAEU5 is the superior among all the other formulations as the hausner’s ratio, % compressibility index and angle of repose is smallest among all the other formulations (Ranjha, Khan, Nazeem, 2010). The bulk and tapped density data are given in Table IV.

**Swelling studies**

The results of swelling studies of all the formulations as compared to CRHPSAI as shown in Figure 1, indicates that with the increase in polymer concentration, the water absorption capacity of the formulations also increase. These studies were done in triplicate. These studies are in confirmation with earlier studies (Xiudong *et al.*, 2004). The statistical studies of the optimized formulation CRSAEU5 is shown in Figure 2.

**Mucoadhesion studies**

As observed from the Table III, CRSAEU5 shows the highest mucoadhesive property. With the increase in both polymer concentrations, there is an increase in mucoadhesion. Also this is supported by results of assessment of duration of mucoadhesion as cited in Table III. As shown in Figure 3, microcapsules adhesioned to the rat intestine of 3 cm² area, where length is 3 cm and breadth is 1 cm.

**In vitro release studies**

The in-vitro release studies were carried out in pH 6.8 phosphate buffer. It was observed that at alkaline pH, greater stress was caused to the polymers thereby causing release of drugs. The microcapsules swelled excessively followed by erosion in the buffered alkaline medium. Eudragit NE30D shows the gelling property in alkaline medium which is considered beneficial for sustaining drug release from the microcapsules. The microcapsules

---

**TABLE IV** - Bulk and tapped density of formulations (Mean ± S.D)

<table>
<thead>
<tr>
<th>Sl.No.</th>
<th>Formulation Code</th>
<th>Weight taken (gm)</th>
<th>Bulk V olume (mL)</th>
<th>Tapped Volume (mL)</th>
<th>Bulk Density B_D (g/mL)</th>
<th>Tapped Density T_D (g/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CRSAEU1</td>
<td>1.0</td>
<td>1.2±0.005</td>
<td>1.1±0.005</td>
<td>0.909±0.005</td>
<td>1.2±0.005</td>
</tr>
<tr>
<td>2</td>
<td>CRSAEU2</td>
<td>1.0</td>
<td>1.2±0.005</td>
<td>1.1±0.005</td>
<td>0.909±0.005</td>
<td>1.2±0.005</td>
</tr>
<tr>
<td>3</td>
<td>CRSAEU3</td>
<td>1.0</td>
<td>0.694±0.002</td>
<td>0.598±0.005</td>
<td>1.666±0.002</td>
<td>0.7±0.005</td>
</tr>
<tr>
<td>4</td>
<td>CRSAEU4</td>
<td>1.0</td>
<td>0.9±0.01</td>
<td>1.0±0.011</td>
<td>1.25±0.01</td>
<td>1.0±0.011</td>
</tr>
<tr>
<td>5</td>
<td><strong>CRSAEU5</strong></td>
<td><strong>1.0</strong></td>
<td><strong>1.3±0.005</strong></td>
<td><strong>0.769±0.005</strong></td>
<td><strong>0.833±0.005</strong></td>
<td><strong>1.3±0.005</strong></td>
</tr>
<tr>
<td>6</td>
<td>CRHPSAI</td>
<td>1.0</td>
<td>0.79±0.006</td>
<td>1.7±0.008</td>
<td>0.555±0.006</td>
<td>0.588±0.008</td>
</tr>
</tbody>
</table>

---

**FIGURE 1** - Comparative % swelling studies of all formulations.

**FIGURE 2** - % swelling studies of formulation CRSAEU5 ± S.D, n=3.

**FIGURE 3** - Swelling time of CRSAEU5.
showed sustained release for a period of 13 hours due to the hindered diffusion of the drug from the gel matrix of Sodium alginate and Eudragit NE30D formed in situ (Sharma, Sarangi, Pradhan 2009) and thereby causing retarded drug release. The release of drugs was retarded with the increase in the polymer ratio. From the Figure 3, it is clearly visible that formulation CRSAEU5 has the highest property of retarding the drug release. The results were compared with Formulation CRHPSAI (devoid of Eudragit NE30D) and it is seen that drug release from CRHPSAI is 98% within 7 hours. Thus Eudragit NE30D is highly effective in retarding the drug release. This study was done in triplicate.

Kinetics of drug release

In order to understand the mechanism and kinetics of invitro drug release, the data were analyzed with various kinetic equations like Zero order (% Cumulative drug release Vs time in hours), First order plot (log of Cumulative % drug released Vs Time), Higuchi model (% Cumulative Drug released Vs Square root of time) and Korsmeyer-Peppas Plot (log% Cumulative drug released Vs log of time). Coefficient of Correlation values were calculated for the linear curves obtained by regression analysis of the above plots.

As observed from Figure 3, it is clear that formulation CRSAEU5 retards the drug release for a longer period of time than in comparison to other formulations, thereby controlling the drug release. From Table V, it is clear that, CRSAEU5 follows first order release mechanism and value of “n” is 0.459 which indicates that the mechanism of the drug to diffusion controlled (Sharma, Sarangi, Pradhan 2009; Mukherjee et al., 2005).

Surface topography

After considering all the parameters of evaluation formulation CRSAEU5 is considered as most efficient. Surface morphologies of the formulation CRSAEU5 as confirmed by SEM studies shows that there are no cracks or crevices present on the surface as shown in Figure 4.

TABLE V - Release kinetics of carvedilol from microcapsules

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Formulation Code</th>
<th>Zero order Kinetics</th>
<th>First order Kinetics</th>
<th>Higuchi Kinetics</th>
<th>Hixson Crowell Kinetics</th>
<th>Korsmeyer-Peppas Kinetics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$R^2$</td>
<td>$k_s$</td>
<td>$R^2$</td>
<td>$k_f$</td>
<td>$R^2$</td>
</tr>
<tr>
<td>1</td>
<td>CRSAEU1</td>
<td>0.964</td>
<td>7.131</td>
<td>0.825</td>
<td>-0.153</td>
<td>0.980</td>
</tr>
<tr>
<td>2</td>
<td>CRSAEU2</td>
<td>0.951</td>
<td>6.654</td>
<td>0.763</td>
<td>-0.138</td>
<td>0.980</td>
</tr>
<tr>
<td>3</td>
<td>CRSAEU3</td>
<td>0.948</td>
<td>6.678</td>
<td>0.827</td>
<td>-0.135</td>
<td>0.976</td>
</tr>
<tr>
<td>4</td>
<td>CRSAEU4</td>
<td>0.967</td>
<td>6.233</td>
<td>0.861</td>
<td>-0.079</td>
<td>0.943</td>
</tr>
<tr>
<td>5</td>
<td>CRSAEU5</td>
<td><strong>0.963</strong></td>
<td><strong>3.520</strong></td>
<td><strong>0.967</strong></td>
<td><strong>-0.022</strong></td>
<td><strong>0.966</strong></td>
</tr>
<tr>
<td>6</td>
<td>CRHPSAI</td>
<td>0.948</td>
<td>14.01</td>
<td>0.938</td>
<td>-0.250</td>
<td>0.984</td>
</tr>
</tbody>
</table>

FIGURE 3 – Comparative Drug Release Profile of microcapsules at pH 6.8; CRSAEU4 (filled (Diamond, Ser.1), CRSAEU1 (Filled Square, Ser.2), CRSAEU5 (Filled triangle, Series 3), CRSAEU2 (Cross, Ser. 4), CRSAEU3 (Star, Ser. 5), CRHPSAI (Filled Circle, Ser. 6), Mean % cumulative drug release±S.D, n=3

FIGURE 4 - Scanning electron microscopy of CRSAEU5.
Zeta potential measurement

The Zeta potential value of CRSAEU5 as seen from Table VI is found to be more towards the positive side than in comparison to the pure drug. The increase in zeta potential may be due to the contribution of HPBCD and Eudragit NE30D. This increase in zeta potential of the formulation also contributes to the increase in mucoadhesive property of the formulation as seen in Table III. This result is in confirmation with earlier studies (Dhawan, Singla, Sinha, 2004).

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Formulation/Polymer/ Drug</th>
<th>Zeta potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CRSAEU5</td>
<td>-20.2</td>
</tr>
<tr>
<td>2</td>
<td>sodium Alginate</td>
<td>-67.3</td>
</tr>
<tr>
<td>3</td>
<td>Eudragit NE30D</td>
<td>-17.2</td>
</tr>
<tr>
<td>4</td>
<td>HPBCD</td>
<td>-19.4</td>
</tr>
<tr>
<td>5</td>
<td>carvedilol</td>
<td>-28.2</td>
</tr>
</tbody>
</table>

TABLE VI - Zeta potential of optimized formulation, polymers, pure drug

FTIR analysis

As observed in Figure 5, FTIR studies indicated weak interactions of carvedilol with HPBCD at 1:1 ratio prepared in the form of microcapsules with different polymers as shown in Figure 7. In carvedilol spectra, absorption peaks were observed at 3349.7701 cm\(^{-1}\), 2933.5562 cm\(^{-1}\) due to hydroxyl and amine stretching respectively. Other peaks were at 1233.5979 cm\(^{-1}\) due to C-O group (epoxides), 1094.8600 cm\(^{-1}\) due to aryl alkyl ethers and alkyl ether C-O stretching respectively. Whereas in the PM, there is an exhibition at 3339.7409 cm\(^{-1}\), 2913.4977 cm\(^{-1}\) due to hydroxyl and amine stretching respectively which matches with pure drug. Also there is an exhibition at 1273.715 cm\(^{-1}\), 1064.77225 cm\(^{-1}\) which matches with that of pure drug showing still the presence of aryl alkyl ethers and alkyl ether C-O stretching respectively. In case of Formulation CRSAEU5, there is appearance of broad wave number of 3261.17844 cm\(^{-1}\) indicating the presence of hydroxyl stretching, and there is very less intensity of presence of 1064.77225 cm\(^{-1}\) indicating the entrapment of carbazol moiety into host cavity during inclusion complex. The results are in confirmation with Hirlekar and Kadam (2009).

XRD analysis

The XRD patterns of pure Carvedilol (CR), physical mixture (PM), pure HPBCD, formulation CRSAEU5 are illustrated in Figure 6 and Figure 7. The diffraction pattern of the physical mixture is simply superimposition or summation of the drug and HPBCD with similar sharp peaks. Nevertheless some changes like peak locations, reduction in peak intensities were observed in the diffractograms of physical Mixture (Table IX) indicating the possibility of some kind of interactions between CR and HPBCD. The formulation also presented a diffraction pattern quite similar to that of physical mixture but with much lower intensities. Also there was disappearance of diffraction peaks of drug in the formulation CRSAEU5. Rajashree Hiralkar et al. found the similar results for CR-MβCD complexes (Hirlekar, Kadam 2009). These phenomena confirmed that an inclusion complex between

FIGURE 5 - FTIR spectra of CRSAEU5, physical mixture (PM), HPBCD, carvedilol, sodium alginate, Eudragit NE30D.

FIGURE 6 - X-ray diffractograms of CRSAEU5, pure carvedilol, pure HPBCD and amorphous carvedilol.
TABLE VII - Peak intensities of CR in XRD patterns of CR-HPBCD systems

<table>
<thead>
<tr>
<th>Sl.No.</th>
<th>2θ (°)</th>
<th>CR</th>
<th>HPBCD</th>
<th>CR:HPBCD</th>
<th>PM</th>
<th>CRSAD4</th>
<th>Amorphous CR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>11.47</td>
<td>102</td>
<td>-----</td>
<td>36</td>
<td>24</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>12.82</td>
<td>158</td>
<td>-----</td>
<td>78</td>
<td>23</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>14.62</td>
<td>130</td>
<td>-----</td>
<td>118</td>
<td>44</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>17.32</td>
<td>630</td>
<td>15</td>
<td>223</td>
<td>92</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>24.100</td>
<td>186</td>
<td>10</td>
<td>158</td>
<td>47</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>26.110</td>
<td>152</td>
<td>-----</td>
<td>124</td>
<td>39</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>29.170</td>
<td>151</td>
<td>-----</td>
<td>48</td>
<td>35</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

the CR and HPBCD. The results in Table VII showed the crystalline characteristics of the drug CR disappeared when complexed with HPBCD as seen in CRSAD5. Moreover, the peak intensities were found to be reduced in amorphous CR.

DSC analysis

DSC studies can be used for the recognition of inclusion complexes (Hirlekar, Kadam, 2009). When the guest molecules were embedded in cyclodextrin cavity, their melting point, boiling or sublimation points generally shifted to a different temperature (Magnusdottir, Masson, Loftsson, 2002). The thermograms of CR along with Physical mixtures, formulation CRSAEU5 and Pure HPBCD are shown in Figure 8. The thermogram of CR was typical of a highly crystalline compound characterized by a sharp endothermic peak at 118 °C which corresponded to its melting point too (Miro et al., 2006). The DSC thermogram of HPBCD showed a broad endotherm which attained a maximum around 100 °C due to release of water molecules. The PM also did not retain the drug endothermic peak and showed a broad peak at 100.91 °C which showed that the complex of the drug and HPBCD in solution state loses the crystalline properties of the drug and thus converts the drug amorphous. Similarly, formulation CRSAEU5 showed broad endothermic peak at 95-105 °C. This may be due to the shift of characteristics peak of CR, which was observed at 117 °C, thereby indicating weak interaction of drug CR with HPBCD. This indicates that there is formation of an amorphous drug, thereby indicating the formation of Inclusion Complex of CR in HPBCD.

FIGURE 7 - X-ray diffractograms of Physical mixtures carvedilol with HPBCD in a ratio of 1:1.

FIGURE 8 - DSC thermograms of CRSAEU5, pure carvedilol(CR), pure hydroxypropyl beta-cyclodextrin (HPBCD), physical mixture (CR+HPBCD+EU) and pure Eudragit NE30D(EU).
**Invivo animal studies**

The *in vivo* studies were carried out with the optimized formulation CRSAEU5 in Swiss albino mice to study the effect of microcapsules. For this purpose, the decrease in blood pressure was observed in hypertension induced mice (with diet mentioned in Table II), which were treated with CRSAEU5 formulation. The results were compared with group treated alone with pure drug CR and Control group. The effects were observed after 24 h from the day of treatment. The data of the blood pressure are presented in Figure 9.

From the Figure 9, it is clear that, the microcapsule formulation coded as CRSAEU5, was effective in decreasing the blood pressure as compared to pure drug group. This may be due to the increase in drug solubility in the body fluids by inclusion of complexing agent in the formulation.

The *in vivo* statistical ANOVA studies are shown in Figure 10, which shows that CRSAEU5 is most effective in controlling the hypertension in comparison to the pure drug. As the pure drug is lipophilic and very less bioavailable, but in the formulation the drug is complexed with HPBCD, thus the hydrophilicity of the drug is enhanced and thus it becomes more bioavailable.

**FIGURE 9** – *In vivo* studies of hypertension in mice.
CONCLUSIONS

In this study, co-grinding technique has been applied to produce inclusion complex of CR with HPBCD and then incorporating this inclusion complex in the polymer matrix by using orifice gelation technique by use of a mixture of polymers Eudragit NE30D and sodium alginate which resulted in smooth, free flowing microcapsules having improved drug delivery. Higher drug loading efficiency was observed for all the formulations, and also the drug release was observed for a period of 13 h. Thus the polymer Eudragit NE30D, showed promising result in retarding drug release. Moreover Eudragit NE30D did not show any incompatibility with neither the inclusion complex nor with the other polymer, i.e. with sodium alginate. Morphological analysis by Scanning Electron Microscopy showed that the formulations were almost spherical in shape and size. All the analytical studies showed that the drug and HPBCD had weak interactions leading to inclusion of drug carvedilol in the cyclodextrin cavity thereby improving the dissolution profile of the drug. The in vivo animal studies showed that the optimized formulation was effective in controlling the hypertension for a period of 24 h.

ACKNOWLEDGEMENTS

Authors wish to thank Glenmark Pharmaceuticals, India, for providing Carvedilol as gift sample, thanks to Roquette, Lestrem, France for providing gift sample of Hydroxy propyl beta cyclodextrin, and also heartiest thanks to Evonik Degussa rohm Pharma, India, for providing gift sample of Eudragit NE 30D. Authors wish to thank CIF, BIT, Mesra, Ranchi for providing all the technical help in completing this study.

List of Abbreviations

CR: Carvedilol
HPBCD: Hydroxypropyl beta-cyclodextrin
EU: Eudragit NE30D
SA: sodium alginate
SEM: Scanning electron microscopy
FTIR: Fourier Transform Infrared Spectroscopy
XRD: X-ray diffraction
DSC: Differential scanning Calorimetry
Ci: Compressibility Index

REFERENCES


Received for publication on 03rd September 2012
Accepted for publication on 21st August 2013